{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:07:46Z","timestamp":1760659666721,"version":"build-2065373602"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T00:00:00Z","timestamp":1755907200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.biopha.2025.118487","type":"journal-article","created":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T13:58:39Z","timestamp":1756475919000},"page":"118487","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Discovery of a novel STAT3 inhibitor: A potential application for pancreatic cancer treatment"],"prefix":"10.1016","volume":"191","author":[{"given":"Xiaoyu","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4976-4883","authenticated-orcid":false,"given":"Chia-Nung","family":"Hung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1360-077X","authenticated-orcid":false,"given":"Meagan","family":"Ybarra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Villarreal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pawel","family":"Osmulski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria E.","family":"Gaczynska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chelliah","family":"Selvam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danmeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8196-6183","authenticated-orcid":false,"given":"Kenneth L.","family":"Kho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Glenn A.","family":"Halff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A.","family":"Ostrov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5596-6265","authenticated-orcid":false,"given":"Addanki P.","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.biopha.2025.118487_bib1","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1001\/jama.2021.13027","article-title":"Pancreatic cancer: a review","volume":"326","author":"Park","year":"2021","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.biopha.2025.118487_bib2","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","article-title":"Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States","volume":"74","author":"Rahib","year":"2014","journal-title":"Cancer Res."},{"issue":"20","key":"10.1016\/j.biopha.2025.118487_bib3","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1001\/jama.2021.18859","article-title":"Incidence of pancreatic cancer by age and sex in the US, 2000-2018","volume":"326","author":"Gaddam","year":"2021","journal-title":"JAMA"},{"issue":"10242","key":"10.1016\/j.biopha.2025.118487_bib4","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1016\/S0140-6736(20)30974-0","article-title":"Pancreatic cancer","volume":"395","author":"Mizrahi","year":"2020","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.biopha.2025.118487_bib5","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/j.cell.2023.02.014","article-title":"Pancreatic cancer: advances and challenges","volume":"186","author":"Halbrook","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2025.118487_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2021.06.027","article-title":"Advances in the epidemiology of pancreatic cancer: trends, risk factors, screening, and prognosis","volume":"520","author":"Cai","year":"2021","journal-title":"Cancer Lett."},{"issue":"18","key":"10.1016\/j.biopha.2025.118487_bib7","doi-asserted-by":"crossref","first-page":"7635","DOI":"10.18632\/aging.204310","article-title":"A comprehensive review of pancreatic cancer and its therapeutic challenges","volume":"14","author":"Jiang","year":"2022","journal-title":"Aging (Albany NY)"},{"key":"10.1016\/j.biopha.2025.118487_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102180","article-title":"Treatment landscape of metastatic pancreatic cancer","author":"De Dosso","year":"2021","journal-title":"Cancer Treat. Rev."},{"issue":"3","key":"10.1016\/j.biopha.2025.118487_bib9","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1634\/theoncologist.3-3-178","article-title":"Pancreatic cancer: local success and distant failure","volume":"3","author":"Ryan","year":"1998","journal-title":"Oncologist"},{"key":"10.1016\/j.biopha.2025.118487_bib10","article-title":"Pancreatic cancer","volume":"2","author":"Kleeff","year":"2016","journal-title":"Nat. Rev. Dis. Prim."},{"issue":"7","key":"10.1016\/j.biopha.2025.118487_bib11","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1053\/j.gastro.2019.01.259","article-title":"Early detection of pancreatic cancer: opportunities and challenges","volume":"156","author":"Singhi","year":"2019","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.biopha.2025.118487_bib12","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/00000441-198802000-00001","article-title":"Continuous 5-fluorouracil (5FU) infusion in carcinoma of the pancreas: a phase II study","volume":"295","author":"Hansen","year":"1988","journal-title":"Am. J. Med. Sci."},{"issue":"42","key":"10.1016\/j.biopha.2025.118487_bib13","doi-asserted-by":"crossref","first-page":"15682","DOI":"10.3748\/wjg.v20.i42.15682","article-title":"Recent studies of 5-fluorouracil resistance in pancreatic cancer","volume":"20","author":"Wang","year":"2014","journal-title":"World J. Gastroenterol."},{"issue":"6","key":"10.1016\/j.biopha.2025.118487_bib14","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","article-title":"Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial","volume":"15","author":"Burris","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2025.118487_bib15","first-page":"8","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"365","author":"Vaccaro","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2025.118487_bib16","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2025.118487_bib17","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1200\/JCO.2011.36.5742","article-title":"Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I\/II trial","volume":"29","author":"Von Hoff","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2025.118487_bib18","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-Paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"10409","key":"10.1016\/j.biopha.2025.118487_bib19","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/S0140-6736(23)01366-1","article-title":"NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial","volume":"402","author":"Wainberg","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2025.118487_bib20","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.canlet.2018.01.057","article-title":"Palmatine suppresses glutamine-mediated interaction between pancreatic cancer and stellate cells through simultaneous inhibition of survivin and COL1A1","volume":"419","author":"Chakravarthy","year":"2018","journal-title":"Cancer Lett."},{"issue":"2","key":"10.1016\/j.biopha.2025.118487_bib21","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1002\/mc.22503","article-title":"Downregulation of STAT3\/NF-\u03baB potentiates gemcitabine activity in pancreatic cancer cells","volume":"56","author":"Gong","year":"2017","journal-title":"Mol. Carcinog."},{"issue":"13","key":"10.1016\/j.biopha.2025.118487_bib22","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1002\/jcc.20084","article-title":"UCSF Chimera--a visualization system for exploratory research and analysis","volume":"25","author":"Pettersen","year":"2004","journal-title":"J. Comput. Chem."},{"issue":"5","key":"10.1016\/j.biopha.2025.118487_bib23","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1023\/A:1011115820450","article-title":"DOCK 4.0: search strategies for automated molecular docking of flexible molecule databases","volume":"15","author":"Ewing","year":"2001","journal-title":"J. Comput. Aided Mol. Des."},{"issue":"10","key":"10.1016\/j.biopha.2025.118487_bib24","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.3390\/cancers16101808","article-title":"Driver mutations in pancreatic cancer and opportunities for targeted therapy","volume":"16","author":"Olaoba","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"12","key":"10.1016\/j.biopha.2025.118487_bib25","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1016\/j.drudis.2019.09.002","article-title":"Applying synergy metrics to combination screening data: agreements, disagreements and pitfalls","volume":"24","author":"Vlot","year":"2019","journal-title":"Drug Discov. Today"},{"issue":"5","key":"10.1016\/j.biopha.2025.118487_bib26","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1038\/nprot.2006.339","article-title":"Clonogenic assay of cells in vitro","volume":"1","author":"Franken","year":"2006","journal-title":"Nat. Protoc."},{"issue":"9","key":"10.1016\/j.biopha.2025.118487_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.113067","article-title":"AXL-initiated paracrine activation of pSTAT3 enhances mesenchymal and vasculogenic supportive features of tumor-associated macrophages","volume":"42","author":"Hung","year":"2023","journal-title":"Cell Rep."},{"issue":"4","key":"10.1016\/j.biopha.2025.118487_bib28","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.3390\/ijms22041852","article-title":"Evidence for 2-Methoxyestradiol-Mediated inhibition of receptor tyrosine kinase RON in the management of prostate cancer","volume":"22","author":"Batth","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"12","key":"10.1016\/j.biopha.2025.118487_bib29","doi-asserted-by":"crossref","first-page":"14048","DOI":"10.18632\/oncotarget.7287","article-title":"Crosstalk between RON and androgen receptor signaling in the development of castration resistant prostate cancer","volume":"7","author":"Batth","year":"2016","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.biopha.2025.118487_bib30","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.ddtec.2004.11.007","article-title":"Lead- and drug-like compounds: the rule-of-five revolution","volume":"1","author":"Lipinski","year":"2004","journal-title":"Drug Discov. Today Technol."},{"issue":"5","key":"10.1016\/j.biopha.2025.118487_bib31","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1158\/1078-0432.CCR-13-1664","article-title":"Combined targeting of STAT3\/NF-\u03baB\/COX-2\/EP4 for effective management of pancreatic cancer","volume":"20","author":"Gong","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.biopha.2025.118487_bib32","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.18632\/oncotarget.1810","article-title":"STAT3 down regulates LC3 to inhibit autophagy and pancreatic cancer cell growth","volume":"5","author":"Gong","year":"2014","journal-title":"Oncotarget"},{"issue":"15","key":"10.1016\/j.biopha.2025.118487_bib33","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.2174\/1568026619666190620145052","article-title":"STAT3: a potential drug target for tumor and inflammation","volume":"19","author":"Hu","year":"2019","journal-title":"Curr. Top. Med. Chem."},{"issue":"7","key":"10.1016\/j.biopha.2025.118487_bib34","doi-asserted-by":"crossref","first-page":"415","DOI":"10.5483\/BMBRep.2019.52.7.152","article-title":"Highlighted STAT3 as a potential drug target for cancer therapy","volume":"52","author":"Lee","year":"2019","journal-title":"BMB Rep."},{"issue":"1-2","key":"10.1016\/j.biopha.2025.118487_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/08977194.2018.1473393","article-title":"STAT3: a multifaceted oncoprotein","volume":"36","author":"Guanizo","year":"2018","journal-title":"Growth Factors"},{"issue":"4","key":"10.1016\/j.biopha.2025.118487_bib36","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","article-title":"Targeting the IL-6\/JAK\/STAT3 signaling axis in cancer","volume":"15","author":"Johnson","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.biopha.2025.118487_bib37","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.canlet.2020.05.035","article-title":"STAT3: a key signaling molecule for converting cold to hot tumors","volume":"489","author":"Hu","year":"2020","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.biopha.2025.118487_bib38","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12986-021-00569-w","article-title":"STAT3 phosphorylation in central leptin resistance","volume":"18","author":"Liu","year":"2021","journal-title":"Nutr. Metab. (Lond)"},{"issue":"8","key":"10.1016\/j.biopha.2025.118487_bib39","doi-asserted-by":"crossref","first-page":"956","DOI":"10.3390\/biomedicines9080956","article-title":"The roles of post-translational modifications in STAT3 biological activities and functions","volume":"9","author":"Tesoriere","year":"2021","journal-title":"Biomedicines"},{"issue":"14","key":"10.1016\/j.biopha.2025.118487_bib40","doi-asserted-by":"crossref","first-page":"5020","DOI":"10.1158\/0008-5472.CAN-11-0908","article-title":"STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesis","volume":"71","author":"Corcoran","year":"2011","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.biopha.2025.118487_bib41","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.ccr.2011.03.002","article-title":"Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression","volume":"19","author":"Fukuda","year":"2011","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.biopha.2025.118487_bib42","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ccr.2011.03.009","article-title":"Stat3\/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer","volume":"19","author":"Lesina","year":"2011","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.biopha.2025.118487_bib43","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/S0016-5085(03)01064-3","article-title":"Activated signal transducer and activator of transcription 3 (STAT3) supports the malignant phenotype of human pancreatic cancer","volume":"125","author":"Scholz","year":"2003","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.biopha.2025.118487_bib44","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0304-3835(03)00482-8","article-title":"Blockade of constitutively activated janus kinase\/signal transducer and activator of transcription-3 pathway inhibits growth of human pancreatic cancer","volume":"201","author":"Toyonaga","year":"2003","journal-title":"Cancer Lett."},{"issue":"5","key":"10.1016\/j.biopha.2025.118487_bib45","doi-asserted-by":"crossref","first-page":"20","DOI":"10.37349\/etat.2024.00202","article-title":"Role of STAT3 in pancreatic cancer","volume":"5","author":"Hamel","year":"2024","journal-title":"Explor Target Antitumor Ther."},{"key":"10.1016\/j.biopha.2025.118487_bib46","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.ejmech.2018.10.067","article-title":"A novel series of napabucasin derivatives as orally active inhibitors of signal transducer and activator of transcription 3 (STAT3)","volume":"162","author":"Li","year":"2019","journal-title":"Eur. J. Med Chem."},{"issue":"2","key":"10.1016\/j.biopha.2025.118487_bib47","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41568-018-0090-8","article-title":"Therapeutically exploiting STAT3 activity in cancer - using tissue repair as a road map","volume":"19","author":"Huynh","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.biopha.2025.118487_bib48","unstructured":"Boston Biomedical, Inc. Announces Update on Phase 3 Canstem111p Study of Napabucasin in Patients with Metastatic Pancreatic Cancer Following Interim Analysis. Boston Biomedical. Published July 1, 2019. \u3008https:\/\/bit.ly\/2Nv0m3F\u3009."},{"issue":"3","key":"10.1016\/j.biopha.2025.118487_bib49","first-page":"iii150","article-title":"A phase Ib\/II study of cancer stemness inhibitor napabucasin in combination with gemcitabine (gem) & nab-paclitaxel (nabPTX) in metastatic pancreatic adenocarcinoma (mPDAC) patients (pts)","volume":"28","author":"Starodub","year":"2017","journal-title":"Ann. Oncol."},{"issue":"12","key":"10.1016\/j.biopha.2025.118487_bib50","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.2217\/fon-2018-0903","article-title":"CanStem111P trial: a phase III study of napabucasin plus nab-paclitaxel with gemcitabine","volume":"15","author":"Sonbol","year":"2019","journal-title":"Future Oncol."},{"issue":"8","key":"10.1016\/j.biopha.2025.118487_bib51","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1038\/s41388-020-01626-z","article-title":"Targeting STAT3 by a small molecule suppresses pancreatic cancer progression","volume":"40","author":"Chen","year":"2021","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.biopha.2025.118487_bib52","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s00262-020-02701-w","article-title":"Response to radiotherapy in pancreatic ductal adenocarcinoma is enhanced by inhibition of myeloid-derived suppressor cells using STAT3 anti-sense oligonucleotide","volume":"70","author":"Oweida","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"issue":"6","key":"10.1016\/j.biopha.2025.118487_bib53","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1007\/s40495-017-0112-3","article-title":"Pancreatic cancer: status and challenges","volume":"3","author":"Mu\u00f1oz","year":"2017","journal-title":"Curr. Pharm. Rep."},{"issue":"5","key":"10.1016\/j.biopha.2025.118487_bib54","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1158\/1078-0432.CCR-13-1664","article-title":"Combined targeting of STAT3\/NF-\u03baB\/COX-2\/EP4 for effective management of pancreatic cancer","volume":"20","author":"Gong","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.biopha.2025.118487_bib55","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1002\/mc.22503","article-title":"Downregulation of STAT3\/NF-\u03baB potentiates gemcitabine activity in pancreatic cancer cells","volume":"56","author":"Gong","year":"2017","journal-title":"Mol. Carcinog."},{"key":"10.1016\/j.biopha.2025.118487_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112122","article-title":"Allosteric inhibitors of the STAT3 signaling pathway","volume":"190","author":"Qin","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.biopha.2025.118487_bib57","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.cytogfr.2019.10.005","article-title":"Novel activators and small-molecule inhibitors of STAT3 in cancer","volume":"49","author":"Yang","year":"2019","journal-title":"Cytokine Growth Factor Rev."},{"issue":"6","key":"10.1016\/j.biopha.2025.118487_bib58","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19061591","article-title":"Structural biology of STAT3 and its implications for anticancer therapies development","volume":"19","author":"Sgrignani","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"21","key":"10.1016\/j.biopha.2025.118487_bib59","doi-asserted-by":"crossref","first-page":"6661","DOI":"10.1021\/jm050513m","article-title":"Investigation of the binding determinants of phosphopeptides targeted to the SRC homology 2 domain of the signal transducer and activator of transcription 3. Development of a high-affinity peptide inhibitor","volume":"48","author":"Coleman","year":"2005","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.biopha.2025.118487_bib60","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0960-894X(02)01050-8","article-title":"Identification of a high affinity phosphopeptide inhibitor of Stat3","volume":"13","author":"Ren","year":"2003","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"16","key":"10.1016\/j.biopha.2025.118487_bib61","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.154475","article-title":"Axon guidance receptor ROBO3 modulates subtype identity and prognosis via AXL-associated inflammatory network in pancreatic cancer","volume":"7","author":"Krebs","year":"2022","journal-title":"JCI Insight"},{"key":"10.1016\/j.biopha.2025.118487_bib62","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s12896-014-0098-4","article-title":"Development of an enzyme linked immunosorbent assay for detection of cyathane diterpenoids","volume":"14","author":"Shen","year":"2014","journal-title":"BMC Biotechnol."},{"issue":"3","key":"10.1016\/j.biopha.2025.118487_bib63","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s00216-013-7496-7","article-title":"Analysis of cyathane-type diterpenoids from Cyathus striatus and Hericium erinaceus by high-resolution MALDI MS imaging","volume":"406","author":"Bhandari","year":"2014","journal-title":"Anal. Bioanal. Chem."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075333222500681X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075333222500681X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T02:48:03Z","timestamp":1760582883000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S075333222500681X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":63,"alternative-id":["S075333222500681X"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118487","relation":{},"ISSN":["0753-3322"],"issn-type":[{"type":"print","value":"0753-3322"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of a novel STAT3 inhibitor: A potential application for pancreatic cancer treatment","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118487","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118487"}}